Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Abandoning Insulin Pumps

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 02:28pm CEST
By Cara Lombardo 

Johnson & Johnson's Animas Corp. will close and exit the insulin pump business, the company said Thursday, citing increased competition that made selling the pumps unsustainable.

Sales of its Animas Vibe and OneTouch Ping pumps in the U.S. and Canada are discontinued immediately, the company said in a news release. The company said it is still evaluating the timing on exiting markets outside the U.S. and Canada.

J&J said the 90,000 diabetes patients that use Animas products will be offered the option to transfer to a pump from Medtronic PLC. Medtronic has seen demand for its pumps skyrocket after the U.S. Food and Drug and Administration approved two new pumps -- the MiniMed 630G and MiniMed 670G -- within weeks of each other last year.

J&J has been streamlining its business as part of a strategic review. Earlier this year, Chief Executive Alex Gorsky had said the company was evaluating options for its diabetes businesses, including possible sales. The company recorded a $200 million charge in its second quarter, primarily related to the insulin pump business.

J&J said it is continuing to evaluate options for its other diabetes businesses including LifeScan Inc., which makes blood-glucose monitors, and OneTouch products.

"This decision was extremely difficult and comes following the extensive exploration of all other viable options for the Animas business," said Valerie Asbury, general manager of Animas, in prepared remarks.

Animas employs 410 people, but the company didn't say if employees would be laid off.

Write to Cara Lombardo at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/21 JOHNSON & JOHNSON : Judge throws out another talc verdict against Johnson & John..
10/21 JOHNSON & JOHNSON : Taiwan FDA finds problems with three lots of Acuvue contact ..
10/21 JOHNSON & JOHNSON : California judge tosses $417 mln talc cancer verdict against..
10/21 JOHNSON & JOHNSON : Judge tosses $417M award against Johnson & Johnson
10/21 JOHNSON & JOHNSON : Janssen receives two u.s. fda approvals for simponi aria® (g..
10/20 JOHNSON & JOHNSON : Ryan Tedder, Hamdi Ulukaya, Bulgari North America Honored at..
10/20 JOHNSON & JOHNSON : blames price cuts in India for poor show in knee-implant bus..
10/20 Healthcare looking in good shape
10/19 JOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. Food and Drug A..
More news
News from SeekingAlpha
10/21 3 THINGS, OCTOBER 21, 2017 : Celgene's New Gamble, Pluristem Marches On ARS, Jan..
10/20 FDA OKs expanded uses for J&J's Simponi Aria
10/20 The Best DGI Stocks For Young Investors - October 1-12, 2017
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 JOHNSON & JOHNSON : Create Your Own Dividends
Financials ($)
Sales 2017 76 267 M
EBIT 2017 23 526 M
Net income 2017 15 953 M
Debt 2017 16 641 M
Yield 2017 2,35%
P/E ratio 2017 24,46
P/E ratio 2018 19,91
EV / Sales 2017 5,23x
EV / Sales 2018 4,84x
Capitalization 382 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 144 $
Spread / Average Target 1,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223
AMGEN27.41%133 501